Sugi Predict

Sugi Predict / Targets / EEA1

EEA1

Early endosome antigen 1 · Q15075 · EEA1 on Sugi Atlas →

0 patent compounds predicted against EEA1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EEA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison Between Botox and Magnesium Sulfate Effect in Treatment of Myofascial Pain Trigger Points Within the Masseter Muscle PHASE2/PHASE3NOT_YET_RECRUITING
Azithromycin Plus Hydroxychloroquine for COVID-19 Infection PHASE3WITHDRAWN
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer PHASE2UNKNOWN
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells PHASE1UNKNOWN
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer PHASE1COMPLETED
Safety and Antiviral Activity of a Monoclonal Hepatitis B Antibody (The SAMBA Study) PHASE1RECRUITING
Dose Escalation Study of Immunomodulatory Nanoparticles PHASE1ACTIVE_NOT_RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors PHASE1ACTIVE_NOT_RECRUITING
Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer PHASE1COMPLETED
IVAC MUTANOME Phase I Clinical Trial PHASE1COMPLETED
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants PHASE1COMPLETED
Phase 1 Study of ART5803 in Healthy Participants PHASE1COMPLETED
Experimental Vaccine for Malaria in Adults in Mali PHASE1COMPLETED
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
The Role of DNA and RNA in NGS Analyses for Advaced Stage NSCLC Patients nanRECRUITING
Study of Chediak-Higashi Syndrome nanRECRUITING
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples. nanUNKNOWN
Genetic Determinants and Clinical Consequences of Early-onset Severe Obesity nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EEA1 binder may also engage these)

ProteinNameSimilarity
Q8BL66 — 0.999 Q8BL66 →
P49454 — 0.997 P49454 →
Q8IWJ2 — 0.995 Q8IWJ2 →
Q13439 — 0.993 Q13439 →
Q8NCX0 — 0.993 Q8NCX0 →
Q8CDI7 — 0.992 Q8CDI7 →
Q8CHG3 — 0.991 Q8CHG3 →
Q61595 — 0.990 Q61595 →
Q9Z221 — 0.990 Q9Z221 →
Q7YS99 — 0.989 Q7YS99 →
P97779 — 0.989 P97779 →
D3ZZL9 — 0.989 D3ZZL9 →
Q7FAD5 — 0.989 Q7FAD5 →
NUMA1 Nuclear mitotic apparatus protein 1 0.989 landscape →
UACA Uveal autoantigen with coiled-coil domains and ankyrin repeats 0.988 landscape →
Q9PW73 — 0.988 Q9PW73 →
Q8NB25 — 0.988 Q8NB25 →
Q92805 — 0.987 Q92805 →
Q6ZU80 — 0.987 Q6ZU80 →
Q15643 — 0.987 Q15643 →
Q9WVQ0 — 0.987 Q9WVQ0 →
Q14789 — 0.987 Q14789 →
O42184 — 0.987 O42184 →
E9Q7G0 — 0.987 E9Q7G0 →
Q5T9S5 — 0.987 Q5T9S5 →
Q9BV73 — 0.986 Q9BV73 →
Q9GL21 — 0.986 Q9GL21 →
Q9P0K7 — 0.986 Q9P0K7 →
A0A8M9PQ61 — 0.985 A0A8M9PQ61 →
Q5U312 — 0.985 Q5U312 →